Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,894 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,160 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01802684 | OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer(VELVET) | completed | Phase 2 | 49 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00303875 | Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight | completed | Phase 2 | 641 | Duke UniversityOTHER | 1 |
| Feb 23, 2017 |
| clinicaltrials |
| NCT00361244 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00335504 | Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia | completed | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03053167 | Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients | unknown | Phase 2 | 100 | China Medical University, ChinaOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT02715882 | Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer | unknown | Phase 2 | 40 | BioLab 612 LLCINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00276861 | Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer | terminated | Phase 2 | 10 | University of MiamiOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT01749956 | 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer | completed | Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00203411 | Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer | completed | Phase 2 | 45 | Translational Oncology Research InternationalOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT02965417 | Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients | withdrawn | Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Feb 1, 2017 | clinicaltrials |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT00056030 | Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer | completed | Phase 2 | 73 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 24, 2017 | clinicaltrials |
| NCT01718808 | Cetuximab for Elderly Patients With mCRC | terminated | Phase 2 | 24 | Swiss Cancer InstituteOTHER | 1 | Jan 24, 2017 | clinicaltrials |
| NCT02586610 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | withdrawn | Phase 2 | 0 | Osama Rahma, MDOTHER | 0 | Jan 20, 2017 | clinicaltrials |
| NCT01507103 | Tecemotide (L-BLP25) in Rectal Cancer(SPRINT) | completed | Phase 2 | 124 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jan 13, 2017 | clinicaltrials |
| NCT02694718 | A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer | completed | Phase 2 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02785068 | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Merrimack PharmaceuticalsINDUSTRY | 0 | Jan 11, 2017 | clinicaltrials |
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT00537823 | Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement | terminated | Phase 2 | 9 | Washington University School of MedicineOTHER | 1 | Dec 20, 2016 | clinicaltrials |
| NCT02236884 | The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer | completed | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00081224 | Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum | terminated | Phase 2 | 3 | Alliance for Clinical Trials in OncologyOTHER | 0 | Dec 15, 2016 | clinicaltrials |
| NCT00016952 | Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 2 | 19 | Alliance for Clinical Trials in OncologyOTHER | 2 | Dec 7, 2016 | clinicaltrials |
| NCT00080951 | Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 14 | Alliance for Clinical Trials in OncologyOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT02617134 | CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02077777 | Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway. | completed | Phase 2 | 21 | SOFAR S.p.A.INDUSTRY | 1 | Dec 2, 2016 | clinicaltrials |
| NCT00040391 | A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer | terminated | Phase 2 | — | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT01522677 | A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Edward NelsonOTHER | 1 | Dec 1, 2016 | clinicaltrials |
| NCT02978313 | Cetuximab Monotherapy Maintenance Treatment in mCRC | unknown | Phase 2 / Phase 3 | 500 | Ruijin HospitalOTHER | 0 | Nov 30, 2016 | clinicaltrials |
| NCT01450319 | Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype(MUTEX) | completed | Phase 2 | 73 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Nov 28, 2016 | clinicaltrials |
| NCT01549535 | Polyp Detection With The Peerscope System™ | completed | Phase 2 | 197 | PeerMedical Ltd.INDUSTRY | 3 | Nov 25, 2016 | clinicaltrials |
| NCT00362102 | A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma | completed | Phase 2 | 38 | Eli Lilly and CompanyINDUSTRY | 0 | Nov 22, 2016 | clinicaltrials |
| NCT02045030 | Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer | terminated | Phase 2 | 14 | CR-CSSS Champlain-Charles-Le MoyneOTHER | 1 | Nov 16, 2016 | clinicaltrials |
| NCT00912743 | Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status | completed | Phase 2 | 33 | AstraZenecaINDUSTRY | 1 | Nov 9, 2016 | clinicaltrials |
| NCT02208804 | Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization(SIM) | unknown | Phase 2 / Phase 3 | 25 | UMC UtrechtOTHER | 1 | Nov 9, 2016 | clinicaltrials |
| NCT00527111 | Pre-op Rectal ChemoRad +/- Cetuximab | completed | Phase 2 | 139 | US Oncology ResearchINDUSTRY | 1 | Nov 3, 2016 | clinicaltrials |
| NCT00048126 | A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | completed | Phase 2 | 57 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00048139 | A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | completed | Phase 2 | 52 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00700570 | A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 45 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00778102 | A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer. | completed | Phase 2 | 80 | Hoffmann-La RocheINDUSTRY | 4 | Nov 2, 2016 | clinicaltrials |
| NCT00940303 | OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer | completed | Phase 2 | 97 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01652482 | Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) | completed | Phase 2 | 135 | Genentech, Inc.INDUSTRY | 10 | Nov 2, 2016 | clinicaltrials |
| NCT00813605 | QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma | completed | Phase 2 | 155 | NantCell, Inc.INDUSTRY | 10 | Oct 27, 2016 | clinicaltrials |
| NCT01060423 | TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer(DEBIRITUX) | terminated | Phase 2 | 8 | Hans-Joachim Schmoll, MDOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT02941562 | A Prospective Phase II Randomized Clinical Trial of Preoperative Chemotherapy Combined With Short-course Radiotherapy Versus Conventional Neo-adjuvant Therapy for Locally Advanced Rectal Cancer Implemented by MDT | unknown | Phase 2 | 150 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Oct 24, 2016 | clinicaltrials |
| NCT01043484 | Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer(AVAXEL) | completed | Phase 2 | 90 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT01085331 | MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) | terminated | Phase 1 / Phase 2 | 16 | EMD SeronoINDUSTRY | 3 | Oct 19, 2016 | clinicaltrials |
| NCT00952016 | Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency(MESH) | terminated | Phase 2 | 2 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 14, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Mar 1, 2017source: clinicaltrials